Literature DB >> 7060019

Properties of human melanoma cells resistant to 5-(3',3'-dimethyl-1-triazeno)imidazole-4-carboxamide and other methylating agents.

P G Parsons, S G Smellie, L E Morrison, I P Hayward.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7060019

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  7 in total

1.  Development of alkylating agent-resistant human tumor cell lines.

Authors:  B A Teicher; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

2.  Clinical pharmacokinetics of high-dose DTIC.

Authors:  J M Buesa; E Urréchaga
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

3.  In vivo depletion of O6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue.

Authors:  S M Lee; N Thatcher; D Crowther; G P Margison
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

4.  Cytotoxicity of 5-(3-methyl-1-triazeno)imidazole-4-carboxamide (MTIC) on Mer+, Mer+Rem- and Mer- cell lines: differential potentiation by 3-acetamidobenzamide.

Authors:  J M Lunn; A L Harris
Journal:  Br J Cancer       Date:  1988-01       Impact factor: 7.640

5.  Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma.

Authors:  S M Lee; J A Rafferty; R H Elder; C Y Fan; M Bromley; M Harris; N Thatcher; P M Potter; H J Altermatt; T Perinat-Frey
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

6.  Induced and inherent resistance to alkylating agents in human small-cell bronchial carcinoma xenografts.

Authors:  R Berman; G G Steel
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

7.  Differential chemosensitivity to antifolate drugs between RAS and BRAF melanoma cells.

Authors:  Imanol Arozarena; Ibai Goicoechea; Oihane Erice; Jennnifer Ferguson; Geoffrey P Margison; Claudia Wellbrock
Journal:  Mol Cancer       Date:  2014-06-19       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.